Published in Drug Metab Dispos on March 28, 1974
Adverse nondrug reactions. N Engl J Med (1968) 5.26
Positive direct Coombs tests due to cephalothin. N Engl J Med (1967) 2.26
Metabolic changes associated with the cessation of cigarette smoking. Arch Environ Health (1970) 1.99
Protein binding of diphenylhydantoin and desmethylimipramine in plasma from patients with poor renal function. N Engl J Med (1971) 1.76
Accumulation of normeperidine, an active metabolite of meperidine, in patients with renal failure of cancer. Ann Intern Med (1977) 1.74
Central nervous system excitatory effects of meperidine in cancer patients. Ann Neurol (1983) 1.74
The biotransformation of drugs in renal failure. Am J Med (1977) 1.70
Quinidine elimination in patients with congestive heart failure or poor renal function. N Engl J Med (1974) 1.63
Clinical consequences of polymorphic acetylation of basic drugs. Clin Pharmacol Ther (1977) 1.50
Inhibition of 11beta-hydroxysteroid dehydrogenase by bioflavonoids and their interaction with furosemide and gossypol. J Lab Clin Med (1998) 1.47
Oral gossypol in the treatment of patients with refractory metastatic breast cancer: a phase I/II clinical trial. Breast Cancer Res Treat (2001) 1.46
Influence of disease on binding of drugs to plasma proteins. Ann N Y Acad Sci (1973) 1.43
Adverse drug reactions without drugs. Lancet (1967) 1.42
Relationship between diazepam dose, plasma level, age, and central nervous system depression. Clin Pharmacol Ther (1978) 1.38
Effect of acetylator phenotype on the rate at which procainamide induces antinuclear antibodies and the lupus syndrome. N Engl J Med (1978) 1.37
Polymorphic acetylation procainamide in man. Clin Pharmacol Ther (1975) 1.32
Optimizing metoclopramide control of cisplatin-induced emesis. Ann Intern Med (1984) 1.30
The binding of drugs to plasma proteins and the interpretation of measurements of plasma concentrations of drugs in patients with poor renal function. Am J Med (1977) 1.27
Pharmacodynamic and pharmacokinetic differences between drug enantiomers in humans: an overview. Clin Pharmacol Ther (1986) 1.21
Specific determination of quinidine and (3S)-3-hydroxyquinidine in human serum by high-pressure liquid chromatography. J Lab Clin Med (1977) 1.13
Steady-state serum levels of quinidine and active metabolites in cardiac patients with varying degrees of renal function. Clin Pharmacol Ther (1978) 1.13
Increased urinary enzyme excretion in workers exposed to nephrotoxic chemicals. Am J Med (1984) 1.12
The binding of drugs to plasma proteins from patients with poor renal function. Clin Pharmacokinet (1976) 1.11
Drug metabolism in uremia. Clin Nephrol (1975) 1.09
Some smokers lie. Clin Pharmacol Ther (1994) 1.07
Hydralazine elimination in man. Clin Pharmacol Ther (1974) 1.06
Oral gossypol in the treatment of metastatic adrenal cancer. J Clin Endocrinol Metab (1993) 1.05
The protein binding of some drugs in plasma from patients with alcoholic liver disease. Eur J Clin Pharmacol (1975) 1.05
Gossypol treatment of recurrent adult malignant gliomas. J Neurooncol (1999) 1.03
Gossypol inhibition of mitosis, cyclin D1 and Rb protein in human mammary cancer cells and cyclin-D1 transfected human fibrosarcoma cells. Br J Cancer (1997) 1.02
Aging and renal clearance of procainamide and acetylprocainamide. Clin Pharmacol Ther (1980) 1.01
Alteration of drug-protein binding in renal disease. Clin Pharmacokinet (1984) 0.99
Pulmonary function in the obese patient. Am J Med Sci (1967) 0.97
In vitro acetylation of drugs by human blood cells. Drug Metab Dispos (1975) 0.95
Antibodies to nuclear antigens in patients treated with procainamide or acetylprocainamide. N Engl J Med (1979) 0.94
Stereoselective renal tubular secretion of quinidine and quinine. Clin Pharmacol Ther (1986) 0.94
Unaltered metabolism of antipyrine and tolbutamide in fasting man. Clin Pharmacol Ther (1975) 0.94
Lipophilic beta-blockers inhibit rat skeletal muscle mitochondrial respiration. Pharmacology (1993) 0.94
Shingles, allergies, family medical history, oral contraceptives, and other potential risk factors for systemic lupus erythematosus. Am J Epidemiol (1994) 0.93
The acetylator phenotype of patients with systemic lupus erythematosus. Drug Metab Dispos (1974) 0.93
Breast silicone implants and risk of systemic lupus erythematosus. J Clin Epidemiol (1994) 0.92
Increased excretion of urinary N-acetyl-beta-glucosaminidase in essential hypertension and its decline with antihypertensive therapy. N Engl J Med (1983) 0.92
Elimination of isoniazid in patients with impaired renal function. Am Rev Respir Dis (1973) 0.91
Lupus erythematosus-like disease due to hydrazine. Am J Med (1983) 0.90
Kinetics of metoprine, a lipid-soluble antifolate. Br J Clin Pharmacol (1981) 0.90
N-acetyl-beta-glucosaminidase and beta 2-microglobulin. Their urinary excretion in patients with renal parenchymal disease. Arch Intern Med (1983) 0.90
Comparison of methods of evaluating nephrotoxicity of cis-platinum. Clin Pharmacol Ther (1980) 0.89
Kidney disease and drug metabolism. Med Clin North Am (1974) 0.88
Development of antinuclear antibody in patients treated with high doses of captopril. Arthritis Rheum (1984) 0.88
Rate of drug metabolism in obese volunteers before and during starvation and in azotemic patients. Metabolism (1969) 0.87
Aromatic amines and the pathogenesis of lupus erythematosus. Am J Med (1983) 0.87
Drugs in the elderly. Med Clin North Am (1982) 0.87
Pharmacologically active drug metabolites: therapeutic and toxic activities, plasma and urine data in man, accumulation in renal failure. Clin Pharmacokinet (1977) 0.87
Kidney function and drug action. N Engl J Med (1985) 0.87
Phenytoin in the treatment of diabetic symmetrical polyneuropathy. Clin Pharmacol Ther (1977) 0.87
Aromatic amines and hydrazines drug acetylation, and lupus erythematodes. Hum Genet Suppl (1978) 0.86
Pubertal changes in net renal tubular secretion of digoxin. Clin Pharmacol Ther (1984) 0.86
Gossypol blood levels and inhibition of spermatogenesis in men taking gossypol as a contraceptive. A multicenter, international, dose-finding study. Contraception (2000) 0.86
Acetylation phenotypes and environmental chemical exposure of people with idiopathic systemic lupus erythematosus. Arthritis Rheum (1993) 0.86
The teaching of clinical pharmacology in Europe and North America. Trends Pharmacol Sci (1989) 0.86
Effects of renal disease upon drug disposition. Drug Metab Rev (1978) 0.86
N-acetylprocainamide: an active metabolite of procainamide. Proc Soc Exp Biol Med (1974) 0.86
Pharmacologically active metabolites of drugs and other foreign compounds. Clinical, pharmacological, therapeutic and toxicological considerations. Drugs (1982) 0.85
A controlled clinical trial of the addition of transdermal scopolamine to a standard metoclopramide and dexamethasone antiemetic regimen. J Clin Oncol (1987) 0.84
Acetylator phenotype in idiopathic systemic lupus erythematosus. Arthritis Rheum (1980) 0.84
Pruritus in dialysis patients treated with parenteral lidocaine. N Engl J Med (1977) 0.83
Plasma levels, protein binding, and elimination data of lidocaine and active metabolites in cardiac patients of various ages. Clin Pharmacol Ther (1983) 0.82
Drug therapy in renal failure. Annu Rev Pharmacol Toxicol (1980) 0.82
Aldosterone, 17-hydroxycorticosteroid, 17-ketosteroid, and fluid and electrolyte responses to starvation and selective refeeding. Am J Med Sci (1967) 0.82
Improved method for the measurement of cimetidine in human serum by reverse-phase high-pressure liquid chromatography. J Lab Clin Med (1981) 0.82
Obesity and fasting--effects on drug metabolism and drug action in man. Clin Pharmacol Ther (1977) 0.82
Age and renal clearance of cimetidine. Clin Pharmacol Ther (1982) 0.82
Grapefruit juice and its flavonoids inhibit 11 beta-hydroxysteroid dehydrogenase. Clin Pharmacol Ther (1996) 0.81
Potential artifacts in the use of caffeine to determine acetylation phenotype. Br J Clin Pharmacol (1989) 0.81
A method for measuring naringenin in biological fluids and its disposition from grapefruit juice by man. Pharmacology (1998) 0.81
Cumulation of N-acetylprocainamide, an active metabolite of procainamide, in patients with impaired renal function. Clin Pharmacol Ther (1977) 0.80